Coalinga chrysotile: A short-fibre, amphibole-free, chrysotile: Part VI - Additional evidence for lack of fibrogenicity

Indoor and Built Environment

Volumn 13, Issue 5, 2004, Pages 375-382

  Ilgren, E B ^a  

^a NONE   (United States)

Author keywords

Chrysotile; Coalinga; Fibrogenicity

Indexed keywords

AMPHIBOLE; CHRYSOTILE;

ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FIBROGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INHALATION; LAW SUIT; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG PARENCHYMA; PATHOGENICITY; PRIORITY JOURNAL;

EID: 7444250796     PISSN: 1420326X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1420326X04047764     Document Type: Article

References (38)

1. Ilgren E, Chatfield E: Coalinga fibre - a short, amphibole-free chrysotile. Part 1: Evidence for a lack of fibrogenic activity. Indoor Built Environ 1997;6:264-276.
2. Ilgren E: Coalinga Fibre - a short, amphibole-free chrysotile. Part 4: further evidence for a lack of fibrogenic and tumorigenic activity. Indoor Built Environ 2002;11:171-177.
3. Ilgren E, Chatfield E: Coalinga fibre - a short, amphibole-free chrysotile. Part 2: Evidence for lack of tumorigenic activity. Indoor Built Environ 1998;7:18-31.
4. Ilgren E, Chatfield E: Coalinga fibre - a short, amphibole-free chrysotile. Part 3: Evidence for lack of biopersistence. Indoor Built Environ 1998;7:98-109.
5. Bernstein D, Chevalier J, Smith P: Comparison of Calidria chrysotile asbestos to pure Tremolite: inhalation biopersistence and histopathology following short-term exposure. Inhal Tox 2003;15:1387-1419.
6. McConnell EE, Wagner JC, Skidmore JW, Moore JA: A comparative study of the fibrogenic and carcinogenic effects of UICC Canadian chrysotile B asbestos and glass microfibre (JM 100) in biological effects of man-made mineral fibres (Report on a WHO/IARC meeting) Copenhagen, 20-22 April 1982. 1984 Annex 45:234-242.
7. Wagner JC, Berry GB, Hill RJ, Munday DE, Skidmore JW: Animal experiments with MMM(V)F - effects of inhalation and intrapleural inoculation in rats. In Biological effects of man-made mineral fibres (Report on a WHO/IARC meeting) Copenhagen, 20-22 April 1982. Annex 1984;42:210-235.
8. Ilgren E: Mesotheliomas of Animals: A comprehensive, Tabular Compendium of the World's Literature. CRC Press, Boca Raton, Florida, 1993, 356pp.
9. Crapo J, Barry B, Brody A, O'Neil J: Morphological, morphometric and X ray microanalytical studies on lung tissue of rats exposed to chrysotile asbestos in inhalation chambers. Biological Effects of Mineral Fibres 1980;1: 1:273-283.
10. Pinkerton K, Pratt P, Brody A, Crapo J: Lung injury patterns as a result of exposure to different chrysotile asbestos fibres. Amer Rev Resp Dis 1981;123:21.
11. Pinkerton K, Pratt P, Crapo J: Morphologic lung changes following exposure to chrysotile. Amer Rev Resp Dis 1981;121:251.
12. O'Neil J, Pinkerton K, Crapo C: Lung volume changes in rats exposed to chrysotile asbestos. Amer Rev Resp Dis 1981;123:146.
13. Yeager H, Gerardi D, Nolan R, Kagan E, Langer A: Cytotoxicity of a short-fibre chrysotile asbestos for human alveolar macrophages: preliminary observations. Environ Res 1983;30:224-232.
14. Egliman D, Roberts M: Letter re "Controlled Use of Asbestos". Intl J Occup Environ Health 2004;10:99-103.
15. Conwed v UCC: US District Court, District of Minnesota. 12 September 2002.
16. Conwed v UCC: US District Court, District of Minnesota. 23 September 2003.
17. Crapo J: Affidavit: Exposure to Calidria asbestos and other forms of asbestos and their roles in disease causation, 16 April 2003.
18. Ilgren E: The biology of cleavage fragments: a brief synthesis and analysis of current knowledge. Indoor Built Environ 2004; in press.
19. Ilgren E: Coalinga fibre - a short, amphibole-free chrysotile. Part 6: Lack of amphibole asbestos contamination. Indoor Built Environ 2004; in press.
20. Murphy R, Brookes S, Gaensler E, Gee B, Goldman A, Kleinerman G, Lewinsohn H, Mitchell R, Utell M, Weill H: The diagnosis of nonmalignant diseases related to asbestos: Official statement of the American Thoracic society. Adopted by the ATS Board of Directors, March 1986. Amer Rev Resp Dis 1986;134:363-368.
21. Crapo J: Testimony given in: Monongalia Co., W. Va. 17 March 1992.
22. Crapo J: Testimony given in: Civil Action No. 92-C-8888, Kanawha, Co., W. Va. 4 May 1994.
23. Crapo J: Testimony given in: Civil Action No. 95-8888, Kanawha, Co., W. Va. 5 September 1995.
24. Crapo J: Testimony given in: Fernandez v Union Carbide et al. Civil Action No. 02-21136, 12 September 2003.
25. Ilgren E: Coalinga fibre - a short, amphibole-free chrysotile. Response to the California EPA's Office of Environmental Health Hazard Assessment [OEHHA] Critical Assessment of Ilgren & Chatfield's Studies of Coalinga Chrysotile's Fibrogenicity, Tumorigenicity, and Biopersistence. Indoor Built Environ 2002b;11:243-245.
26. Muhle H, Pott F, Bellman B, Takenaka S, Ziem U: Inhalation and injection experiments in rats to test the carcinogenicity of MMMF. Ann Occup Hyg 1987;131:755-764.
27. BD [Becton Dickinson] Quarterly report, "Effects of chronic exposure to airborne environmental agents", Submitted to NIEHS under contract no. NIEHS-N01-ES-4-2164, Dr Connie Stone, Principal investigator, Dr O.L. Carter, Acting director, I April 1978-31 July 1978.
28. BD [Becton Dickinson] Quarterly report, "Effects of chronic exposure to airborne environmental agents", Submitted to NIEHS under contract no. NIEHS-N01-ES-4-2164, Dr Connie Stone, Principal investigator, Dr O.L. Carter, Acting director, 1 August 1978-31 October 1978.
29. BD [Becton Dickinson] Quarterly report, "Effects of chronic exposure to airborne environmental agents", Submitted to NIEHS under contract no. NIE - NIEHS-N01-ES-4-2164, Dr Connie Stone, Principal investigator, Dr O.L. Carter, Acting director, 1 November 1978-31 January 1979.
30. ATSDR [Agency for Toxic Substances and Disease Registry] Expert Panel on Health Effects of Asbestos and Synthetic Vitreous Fibres and the Influence of Fibre Length. Meeting, New York, 29-30 October 2003.
31. European Directorate General Health and Consumer Protection, Scientific Committee on Toxicity, Ecotoxicity, and the Environment. C2/GF/csteeop/Asbestos 17122002/D(02). Opinion on: Risk to human health from chrysotile asbestos and organic substitutes. 35th CSTEE plenary meeting, Brussels, 17 December 2002.
32. Pinkerton K, Brody A, McLaurin D, Adkins B, O'Connor R, Pratt P, Crapo J: Characterization of three types of chrysotile asbestos after aerosolization. Environ Res 1983;31:32-53.
33. Johnson N, Mossman B: Dose, Dimension, Durability and Biopersistence of Chrysotile Asbestos. Nolan R, Langer A, Ross M, Wicks F, Martin R (eds): The Health Effects of Chrysotile Asbestos: Contribution of Science to Risk Management Decisions. Can Min (Spec. Pub. 5), 1002, pp. 145-154.
34. Hoskins J: Toxicological insight into low-level exposure to chrysotile. Nolan R, Langer A, Ross M, Wicks F, Martin R (eds): The Health Effects of Chrysotile Asbestos: Contribution of Science to Risk Management Decisions. Can Min (Spec. Pub. 5), 2002, pp. 251-259.
35. Roggli V: Testimony given in: Bremer v Metropolitan Life et al., 22 January 2002.
36. Egilman D: Testimony in: Lustgarten v A W Chesterton et al., 26 March 2004.
37. Nolan R, Langer A, Addison J: Lung Content Analysis of Cases Occupationally Exposed to Chrysotile Asbestos Environ Health Perspect. 1994;102 (Suppl 5):245-250.
38. Langer testimony in Conwed v Union Carbide, [2002].